Effects of glibenclamide, glimepiride, and gliclazide on ischemic preconditioning in rat heart

Chinese Medical Sciences Journal

Volumn 22, Issue 3, 2007, Pages 162-168

  Wu, Guo Ting ^a   Wang, Lin ^a   Li, Jun ^b   Zhu, Wei Zhong ^c  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Inwardly rectifying potassium channels; Myocardial ischemic preconditioning; Sulfonylurea compounds

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; SULFONYLUREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; HEART HEMODYNAMICS; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; RAT; SARCOLEMMA; VOLTAGE CLAMP;

ANIMALS; GLICLAZIDE; GLYBURIDE; HEART; ISCHEMIC PRECONDITIONING; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFONYLUREA COMPOUNDS;

EID: 35348869936     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103:3111-6.
2. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65:385-411.
3. Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51:368-76.
4. Riveline JP, Danchin N, Ledru F, et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29:207-22.
5. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18:113-9.
6. Wang WW, Zhu YC, Yao T, et al. Effect of angiotensin II on potassium channels of ischemic ventricular myocytes of the guinea pig. Sheng Li Xue Bao 2002; 54:149-53.
7. Loubani M, Fowler A, Standen NB, et al. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005; 515:142-9.
8. Zhu HF, Dong JW, Zhu WZ, et al. ATP-dependent potassium channels involved in the cardiac protection induced by intermittent hypoxia against ischemia/reperfusion injury. Life Sciences 2003; 73:1275-87.
9. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001; 104:3158-67.
10. Horimoto H, Nakai Y, Mieno S, et al. Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning. J Surg Res 2002; 105:181-8.
11. Grover GJ, Garlid KD. ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 2000; 32:677-95.
12. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K (ATP) channels to gliclazide. Diabetologia 1999; 42:845-8.
13. + channel openers. Pharmacol Ther 2000; 85:39-53.
14. Geisen K, Vegh A, Krause E, et al. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996; 28:496-507.
15. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K (ATP) channels. Br J Pharmacol 2001; 133:193-9.
16. Gribble FM, Tucker SJ, Seino S, et al. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K (ATP) channels. Diabetes 1998; 47:1412-8.